| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyclo(RGDyC) TFA targets integrin receptors, particularly αvβ3 and αvβ5. The RGD motif is the minimal peptide sequence recognized by these integrins. Integrin αvβ3 is overexpressed on activated endothelial cells during angiogenesis and on various cancer cells. By binding to these integrins, the peptide can be used to target tumor vasculature and cancer cells for diagnostic or therapeutic applications.
|
|---|---|
| ln Vitro |
In vitro, Cyclo(RGDyC) TFA is used as a targeting ligand to study integrin-mediated cell adhesion and signaling. The peptide binds to integrin αvβ3 and αvβ5 with high affinity. It can be used to block integrin-ligand interactions, to study integrin-mediated cellular processes such as angiogenesis, cell migration, and metastasis. The peptide is also used to functionalize nanoparticles or other delivery vehicles for targeted drug delivery.
|
| ln Vivo |
In vivo, Cyclo(RGDyC) TFA is used to target tumor vasculature and cancer cells expressing integrin αvβ3 and αvβ5. The peptide can be conjugated to imaging agents for tumor imaging or to therapeutic agents for targeted cancer therapy. Its cyclic structure provides enhanced stability and binding affinity compared to linear RGD peptides. The compound has been extensively studied in preclinical models of cancer.
|
| Enzyme Assay |
Non-cellular binding assays for Cyclo(RGDyC) TFA involve measuring its binding affinity to purified integrin αvβ3 or αvβ5 using techniques such as surface plasmon resonance (SPR), ELISA, or fluorescence polarization. The peptide's ability to inhibit integrin-ligand interactions can also be assessed using competitive binding assays. These assays confirm the peptide's high affinity and specificity for its integrin targets.
|
| Cell Assay |
In vitro cellular experiments with Cyclo(RGDyC) TFA are conducted in integrin-expressing cell lines. Cells are treated with the peptide, and integrin-mediated adhesion, migration, or signaling is assessed. The peptide can be used to block integrin-dependent processes such as cell attachment to extracellular matrix proteins. Fluorescently labeled versions of the peptide are used to study receptor binding and internalization by flow cytometry or fluorescence microscopy.
|
| Animal Protocol |
In vivo animal studies with Cyclo(RGDyC) TFA are performed in murine tumor models. The peptide is conjugated to imaging agents (e.g., fluorescent dyes, radionuclides) or therapeutic agents (e.g., drugs, nanoparticles) and administered intravenously. Tumor targeting is assessed by imaging or by measuring the accumulation of the conjugate in tumor tissue. Therapeutic efficacy is evaluated by monitoring tumor growth and survival.
|
| ADME/Pharmacokinetics |
Cyclo(RGDyC) TFA has the peptide sequence cyclo(Arg-Gly-Asp-D-Tyr-Cys). The TFA salt form enhances solubility. The compound is typically stored at -20°C and protected from light. It is soluble in water and aqueous buffers. Purity is typically ≥95%. The compound is for research use only and not for human therapeutic applications.
|
| Toxicity/Toxicokinetics |
Toxicity data for Cyclo(RGDyC) TFA are typically characterized as part of the safety evaluation of RGD peptide-based imaging or therapeutic agents. The peptide itself is generally well-tolerated. Standard toxicology studies assess the safety of the final conjugate. Researchers should consult the safety data sheet and handle the compound with appropriate laboratory safety precautions.
|
| References |
|
| Additional Infomation |
Cyclo(RGDyC) TFA is a cyclic RGD peptide targeting integrin αvβ3 and αvβ5. The peptide is used for tumor targeting, angiogenesis research, and the development of targeted diagnostic and therapeutic agents. All products are for research use only.
|
| Molecular Formula |
C24H34N8O8S.XC2HF3O2
|
|---|---|
| Molecular Weight |
594.64 (free base)
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
